Analysts Set Cellebrite DI Ltd. (NASDAQ:CLBT) Price Target at $21.75

Cellebrite DI Ltd. (NASDAQ:CLBT) has been assigned a consensus rating of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $21.75.

CLBT has been the subject of several research analyst reports. Needham & Company LLC cut their price objective on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, August 14th. Wall Street Zen raised Cellebrite DI from a “hold” rating to a “buy” rating in a report on Friday, September 26th. JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a report on Wednesday, September 24th. Lake Street Capital cut their price objective on Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday, August 15th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Cellebrite DI in a report on Wednesday, October 8th.

Cellebrite DI Trading Up 0.9%

Cellebrite DI stock opened at $16.05 on Monday. The firm has a market cap of $3.84 billion, a price-to-earnings ratio of -21.12, a PEG ratio of 3.16 and a beta of 1.28. The stock has a fifty day simple moving average of $17.81 and a two-hundred day simple moving average of $16.81. Cellebrite DI has a 12 month low of $13.10 and a 12 month high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. The business had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The company’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 EPS. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts forecast that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellebrite DI

Several institutional investors and hedge funds have recently bought and sold shares of CLBT. Wealth Enhancement Advisory Services LLC purchased a new position in Cellebrite DI during the first quarter valued at $269,000. Teacher Retirement System of Texas lifted its position in Cellebrite DI by 121.3% during the first quarter. Teacher Retirement System of Texas now owns 44,407 shares of the company’s stock valued at $863,000 after purchasing an additional 24,337 shares in the last quarter. OneDigital Investment Advisors LLC lifted its position in Cellebrite DI by 2.5% during the first quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company’s stock valued at $556,000 after purchasing an additional 688 shares in the last quarter. Catalyst Capital Advisors LLC purchased a new position in Cellebrite DI during the first quarter valued at $51,000. Finally, Bank of New York Mellon Corp purchased a new position in Cellebrite DI during the first quarter valued at $22,428,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.